Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
34 pending office actions • 26 clients • 33 examiners • 29 art units • 0 of 34 (0%) have an AI response strategy ready • 39 patents granted in the last 365 days
HULTQUIST IP has 37 pending office actions in Biotechnology & Pharmaceuticals and 2995 career applications. Its resolved allowance rate is 77.79%, and the average is 3.69 office actions per allowance.
The profile shows a substantial historical application base and an active biotechnology and pharmaceutical docket. The resolved allowance rate describes completed prosecution outcomes, while the office-action average reflects the examination effort associated with allowances. This combination can support staffing and response planning without treating historical results as a prediction for each pending matter.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (3%) |
| §101 + other | 6 (18%) |
| §103 only | 5 (15%) |
| §102 only | 1 (3%) |
| §112 only | 3 (9%) |
| Double-patenting + other | 2 (6%) |
| Multi-statute (no §101) | 16 (47%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIKNIS, ZACHARY J | 2 | 68.5% | +32.4% |
| NGUYEN, KATHLEEN V | 1 | 67.3% | +25.7% |
| MUKHOPADHYAY, BHASKAR | 1 | 28.2% | +37.0% |
| CRUM, MARY ABOU NADER | 1 | 39.2% | +63.7% |
| HELM, CARALYNNE E | 1 | 28.9% | +49.8% |
| PAK, YONG D | 1 | 74.7% | +14.2% |
| DUBOIS, PHILIP A | 1 | 25.6% | +26.3% |
| LAWRENCE JR, FRANK M | 1 | 83.8% | +20.0% |
| SAOUD, CHRISTINE J | 1 | 57.9% | +37.5% |
| CHEN, STACY BROWN | 1 | 66.1% | +40.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18822019 | Metal Oxide Compounds with Enhanced Reactivity | HELM, CARALYNNE E | 8d overdue |
| 18681047 | METHOD FOR PRODUCTION OF AMMONIA, USING INORGANIC NANOPARTICLE-MICROBIAL COMPLEX | BREEN, KIMBERLY CATHERINE | 8d |
| 18551590 | TARGET NUCLEIC ACID AMPLIFICATION METHOD USING GUIDE PROBE AND CLAMPING PROBE AND COMPOSITION FOR AMPLIFYING TARGET NUCLEIC ACID COMPRISING SAME | JONES, CHRISTINE MICHELLE | 27d |
| 18570202 | USE OF LACTOBACILLUS FERMENTUM STRAIN AND REGULATORY T CELLS FOR COMBINATION THERAPY FOR PREVENTION OR TREATMENT OF METABOLIC DISEASES | GORDON, MELENIE LEE | 41d |
| 18852449 | MEASURING DEVICE BASED ON A COMBINATION OF OPTICAL 2D AND 3D IMAGE CAPTURING METHODS | NGUYEN, KATHLEEN V | — |
| 18862545 | DEGRADATION-RESISTANT ALDEHYDE-CONTAINING COMPOSITIONS | MUKHOPADHYAY, BHASKAR | — |
| 18859192 | LACTOBACILLUS PARACASEI STRAIN OR LACTOBACILLUS PLANTARUM STRAIN DERIVED FROM HUMAN BODY, HAVING BODY FAT REDUCING ACTIVITY, AND MIXTURE COMPOSITION COMPRISING SAME | CRUM, MARY ABOU NADER | — |
| 18837131 | NOVEL LIPID PEROXIDATION SYSTEM AND METHOD FOR PREPARING BIOFUEL AND BIOPOLYMER USING SAME | PAK, YONG D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18822019 | Metal Oxide Compounds with Enhanced Reactivity | HELM, CARALYNNE E | 8d overdue |
| 18852449 | MEASURING DEVICE BASED ON A COMBINATION OF OPTICAL 2D AND 3D IMAGE CAPTURING METHODS | NGUYEN, KATHLEEN V | — |
| 18862545 | DEGRADATION-RESISTANT ALDEHYDE-CONTAINING COMPOSITIONS | MUKHOPADHYAY, BHASKAR | — |
| 18859192 | LACTOBACILLUS PARACASEI STRAIN OR LACTOBACILLUS PLANTARUM STRAIN DERIVED FROM HUMAN BODY, HAVING BODY FAT REDUCING ACTIVITY, AND MIXTURE COMPOSITION COMPRISING SAME | CRUM, MARY ABOU NADER | — |
| 18837131 | NOVEL LIPID PEROXIDATION SYSTEM AND METHOD FOR PREPARING BIOFUEL AND BIOPOLYMER USING SAME | PAK, YONG D | — |
| 18755697 | BEVERAGE COMPOSITIONS FOR HYDRATION AND FOR SUPPORT OF HAIR HEALTH | DUBOIS, PHILIP A | — |
| 18716787 | MATERIALS, SYSTEMS, AND PROCESSES FOR PRODUCTION OF HIGH PURITY OXYGEN | LAWRENCE JR, FRANK M | — |
| 18707591 | RESISTIN-SPECIFIC ANTIBODY AND USE THEREOF | SAOUD, CHRISTINE J | — |
| Art Unit | Apps |
|---|---|
| 1658 | 3 |
| 1657 | 2 |
| 1635 | 2 |
| 1653 | 2 |
| 2486 | 1 |
| 1792 | 1 |
| 1615 | 1 |
| 1652 | 1 |
| 1791 | 1 |
| 1776 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18852449 | MEASURING DEVICE BASED ON A COMBINATION OF OPTICAL 2D AND 3D IMAGE CAPTURING METHODS | BESI Switzerland AG | NGUYEN, KATHLEEN V | 2486 | §103§112 | Non-Final OA | — | Pending | May 09, 2025 |
| 18862545 | DEGRADATION-RESISTANT ALDEHYDE-CONTAINING COMPOSITIONS | Zoomessence, Inc. | MUKHOPADHYAY, BHASKAR | 1792 | §103§112 | Non-Final OA | — | Pending | Nov 03, 2024 |
| 18859192 | LACTOBACILLUS PARACASEI STRAIN OR LACTOBACILLUS PLANTARUM STRAIN DERIVED FROM HUMAN BODY, HAVING BODY FAT REDUCING ACTIVITY, AND MIXTURE COMPOSITION COMPRISING SAME | Hecto Health Care Co., Ltd. | CRUM, MARY ABOU NADER | 1657 | §103§112 | Non-Final OA | — | Pending | Oct 23, 2024 |
| 18822019 | Metal Oxide Compounds with Enhanced Reactivity | Nanoionix, LLC | HELM, CARALYNNE E | 1615 | §102§103§112 | Non-Final OA | 8d overdue | Pending | Aug 30, 2024 |
| 18837131 | NOVEL LIPID PEROXIDATION SYSTEM AND METHOD FOR PREPARING BIOFUEL AND BIOPOLYMER USING SAME | Korea Advanced Institute Of Science And Technology | PAK, YONG D | 1652 | §103§112 | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18755697 | BEVERAGE COMPOSITIONS FOR HYDRATION AND FOR SUPPORT OF HAIR HEALTH | Celmatrix Corporation | DUBOIS, PHILIP A | 1791 | §103 | Non-Final OA | — | Pending | Jun 27, 2024 |
| 18716787 | MATERIALS, SYSTEMS, AND PROCESSES FOR PRODUCTION OF HIGH PURITY OXYGEN | Georgia Tech Research Corporation | LAWRENCE JR, FRANK M | 1776 | §102§103§112 | Non-Final OA | — | Pending | Jun 05, 2024 |
| 18707591 | RESISTIN-SPECIFIC ANTIBODY AND USE THEREOF | Kim Cell&Gene | SAOUD, CHRISTINE J | 1645 | §112 | Non-Final OA | — | Pending | May 05, 2024 |
| 18700912 | GENE CONSTRUCT FOR EXPRESSING MRNA | Genomictree, Inc. | CHEN, STACY BROWN | 1672 | §101§102Other | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18681058 | PHOTOCATALYTIC PANEL REACTOR FOR THE ANAEROBIC PHOTOREFORMING OF WASTE AQUEOUS EFFLUENTS AND THE PRODUCTION OF HYDROGEN AS CO-PRODUCT | UNIVERSITAT ROVIRA I VIRGILI | ROTONDI, CONNOR JON | 1779 | §103 | Final Rejection | — | Pending | Feb 04, 2024 |
| 18681047 | METHOD FOR PRODUCTION OF AMMONIA, USING INORGANIC NANOPARTICLE-MICROBIAL COMPLEX | Korea Advanced Institute Of Science And Technology | BREEN, KIMBERLY CATHERINE | 1657 | §102§112 | Final Rejection | 8d | Pending | Feb 03, 2024 |
| 18580971 | COMPOSITION FOR PREVENTING OR TREATING LIVER DISEASES, COMPRISING STC-1 OR DERIVATIVE THEREOF | Industry-Academic Cooperation Foundation, Yonsei University | STEELE, AMBER D | 1658 | §102§103§112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18577810 | SEMICONDUCTOR DEVICE STRUCTURE WITH RECESSED OHMIC CONTACTS AND METHOD FOR PRODUCING THE SAME | Swegan AB | CHEN, JACK S J | 2893 | §103§112 | Non-Final OA | — | Pending | Jan 09, 2024 |
| 18571238 | LIPID NANOPARTICLES AND METHOD FOR PREPARING SAME | Therna Therapeutics | PIPIC, ALMA | 1617 | §103§112 | Non-Final OA | — | Pending | Dec 17, 2023 |
| 18570202 | USE OF LACTOBACILLUS FERMENTUM STRAIN AND REGULATORY T CELLS FOR COMBINATION THERAPY FOR PREVENTION OR TREATMENT OF METABOLIC DISEASES | Gi Biome | GORDON, MELENIE LEE | 1651 | §102§103§112Other | Non-Final OA | 41d | Pending | Dec 14, 2023 |
| 18567167 | NANOPARTICLE COMPRISING PEPTIDE-LIPID CONJUGATE FOR DELIVERING OLIGONUCLEOTIDE INTO TARGET CELL AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Seoul National University R&Db Foundation | SHIN, DANA H | 1635 | §112 | Non-Final OA | — | Pending | Dec 05, 2023 |
| 18513613 | COMPOSITION FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE OR NON-ALCOHOLIC STEATOHEPATITIS COMPRISING GROWTH DIFFERENTIATION FACTOR-15 VARIANT | Yuhan Corporation | MIKNIS, ZACHARY J | 1658 | §101§102§112DP | Non-Final OA | — | Pending | Nov 19, 2023 |
| 18562322 | COMPOSITION FOR COMBINATION THERAPY COMPRISING GROWTH DIFFERENTIATION FACTOR-15 VARIANT AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST | Yuhan Corporation | MIKNIS, ZACHARY J | 1658 | §101§102§112 | Non-Final OA | — | Pending | Nov 19, 2023 |
| 18513527 | BEVERAGE COMPOSITIONS FOR HYDRATION AND FOR SUPPORT OF HAIR HEALTH | Celmatrix Corporation | GREENE, IVAN A | 1619 | §102§103§112Other | Non-Final OA | — | Pending | Nov 18, 2023 |
| 18559052 | ARTIFICIAL INTELLIGENCE-BASED METHOD FOR EARLY DIAGNOSIS OF CANCER, USING CELL-FREE DNA DISTRIBUTION IN TISSUE-SPECIFIC REGULATORY REGION | Korea Advanced Institute Of Science And Technology | ELKINS, BLAKE HARRISON | 1687 | §101§103§112Other | Non-Final OA | — | Pending | Nov 05, 2023 |
| 18551590 | TARGET NUCLEIC ACID AMPLIFICATION METHOD USING GUIDE PROBE AND CLAMPING PROBE AND COMPOSITION FOR AMPLIFYING TARGET NUCLEIC ACID COMPRISING SAME | Hlb Panagene Co., Ltd. | JONES, CHRISTINE MICHELLE | 1682 | §102§103§112 | Final Rejection | 27d | Pending | Sep 20, 2023 |
| 18548539 | ELECTROLYTE SOLUTION FOR SECONDARY BATTERY, AND SECONDARY BATTERY COMPRISING SAME | Dongwha Electrolyte Co., Ltd. | DOMONE, CHRISTOPHER P | 1725 | §102 | Final Rejection | — | Pending | Aug 31, 2023 |
| 18262543 | PEPTIDE FOR PREVENTING AND TREATING FIBROSIS | Seoul National University R&Db Foundation | SCHWECHTER, BRANDON ROSS | 1674 | §102§112Other | Non-Final OA | — | Pending | Jul 21, 2023 |
| 18261882 | COMPOSITION FOR ALLEVIATING HAIR GRAYING, PROMOTING HAIR GROWTH AND/OR PREVENTING OR ALLEVIATING HAIR LOSS, COMPRISING DOUBLE-STRANDED MIRNA AS ACTIVE INGREDIENT | Sirnagen Therapeutics Corporation | YU, DAVID TUYANG | 1635 | §103§112 | Non-Final OA | — | Pending | Jul 18, 2023 |
| 18254126 | TARGET NUCLEIC ACID AMPLIFICATION METHOD WITH HIGH SPECIFICITY AND TARGET NUCLEIC ACID AMPLIFYING COMPOSITION USING SAME | Panagene Inc. | KIM, YOUNG J | 1681 | §103Other | Final Rejection | — | Pending | May 23, 2023 |
| 18251033 | METHOD FOR DETERMINING SENSITIVITY TO PARP INHIBITOR OR DNA DAMAGING AGENT USING NON-FUNCTIONAL TRANSCRIPTOME | Korea Advanced Institute Of Science And Technology | HOPPE, EMMA RUTH | 1683 | §112 | Final Rejection | 29d | Pending | Apr 28, 2023 |
| 18168613 | LOW-COST ENGINEERED PARTICLES FOR THERMAL ENERGY TRANSFER OR STORAGE | Advanced Materials Scientia LLC | WALKER, AJA ARYANNA | 1761 | §103§112DP | Non-Final OA | — | Pending | Feb 14, 2023 |
| 17907432 | COMPOSITION USING URINE SAMPLE FOR DIAGNOSIS OF KIDNEY DISEASE | Soonchunhyang University Industry Academy Cooperation Foundation | EVANS, CHRISTOPHER RYAN | 1677 | §101§103 | Non-Final OA | — | Pending | Sep 27, 2022 |
| 17759872 | COMPOSITION FOR TREATING CLIMACTERIC DISORDER COMPRISING LACTOBACILLUS GASSERI BNR17 | Acebiome Inc. | KOROTCHKINA, LIOUBOV G | 1653 | §103§112DP | Non-Final OA | — | Pending | Aug 01, 2022 |
| 17635220 | METHOD FOR DETECTING CHROMOSOMAL ABNORMALITY BY USING INFORMATION ABOUT DISTANCE BETWEEN NUCLEIC ACID FRAGMENTS | Green Cross Genome Corporation | SMITH, JENNIFER JOY | 1685 | §101§103 | Final Rejection | — | Pending | Jul 15, 2022 |
| 17784740 | METHOD FOR PREPARING MESENCHYMAL STEM CELLS HAVING IMPROVED VIABILITY THROUGH ANTI-CANCER VIRUS INTRODUCTION | Jeong Chan Ra | SMALL, KATHERINE R | 1633 | §102§103 | Non-Final OA | — | Pending | Jun 13, 2022 |
| 17780813 | ARTIFICIAL INTELLIGENCE-BASED CHROMOSOMAL ABNORMALITY DETECTION METHOD | Gc Genome Corporation | KRIANGCHAIVECH, KETTIP | 1686 | §101Other | Final Rejection | — | Pending | May 27, 2022 |
| 17598199 | SPRAY-DRIED POWDERS | Zoomessence, Inc. | GWARTNEY, ELIZABETH A | 1759 | §103 | Final Rejection | 98d overdue | Pending | Sep 24, 2021 |
| 14890585 | STEM CELL COMPOSITION FOR VENOUS ADMINISTRATION | Jeong-Chan Ra | MOSS, NATALIE M | 1653 | §103 | Final Rejection | 4d overdue | Pending | Nov 11, 2015 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial77.8% of resolved applications prosecuted by Hultquist Ip were allowed, across 2,995 applications in USPTO records.
3.69 office actions per allowed application on average.
34 pending office actions as of October 2026, for 26 clients, before 33 examiners in 29 art units.
